Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Most Cited Paper
in Hepatocellular Carcinoma Treatment and Prognosis
18 Months Post-Publication
Class of 2026
“Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026/
Topics
Hepatocellular carcinoma · nivolumab · ipilimumab · combination immunotherapy · sorafenib · CheckMate 040 · PD-1/PD-L1 inhibitor · CTLA-4 inhibition · Immune checkpoint inhibitor therapy · Objective response rate · Duration of response · Overall survival · Second-line therapy · Advanced hepatocellular carcinoma · Immune-related adverse events · RECIST 1.1 · long-term survival benefit · Durable response · safety and tolerability · landmark analysis · randomized cohort · Sorafenib-experienced · 5-year follow-up · dose regimen optimization · immune-oncology combination therapy
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026. https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459